A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers

Cell Rep. 2018 Apr 10;23(2):584-595. doi: 10.1016/j.celrep.2018.03.061.

Abstract

The heavily glycosylated native-like envelope (Env) trimer of HIV-1 is expected to have low immunogenicity, whereas misfolded forms are often highly immunogenic. High-quality correctly folded Envs may therefore be critical for developing a vaccine that induces broadly neutralizing antibodies. Moreover, the high variability of Env may require immunizations with multiple Envs. Here, we report a universal strategy that provides for correctly folded Env trimers of high quality and yield through a repair-and-stabilize approach. In the repair stage, we utilized a consensus strategy that substituted rare strain-specific residues with more prevalent ones. The stabilization stage involved structure-based design and experimental assessment confirmed by crystallographic feedback. Regions important for the refolding of Env were targeted for stabilization. Notably, the α9-helix and an intersubunit β sheet proved to be critical for trimer stability. Our approach provides a means to produce prefusion-closed Env trimers from diverse HIV-1 strains, a substantial advance for vaccine development.

Keywords: ConC_base; HIV; SOSIP; X-ray structure; chronic; envelope protein; hybrid sheet; stabilization; transmitted/founder; vaccine.

MeSH terms

  • Calorimetry, Differential Scanning
  • Crystallography, X-Ray
  • HIV Antibodies / chemistry
  • HIV Antibodies / metabolism
  • HIV-1 / metabolism*
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Mutagenesis, Site-Directed
  • Protein Conformation, alpha-Helical
  • Protein Conformation, beta-Strand
  • Protein Multimerization
  • Protein Refolding
  • Protein Stability
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / isolation & purification
  • env Gene Products, Human Immunodeficiency Virus / chemistry
  • env Gene Products, Human Immunodeficiency Virus / genetics
  • env Gene Products, Human Immunodeficiency Virus / metabolism*

Substances

  • HIV Antibodies
  • Recombinant Proteins
  • env Gene Products, Human Immunodeficiency Virus